These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18408886)

  • 1. Pharmacological manipulation of L-carnitine transport into L6 cells with stable overexpression of human OCTN2.
    Todesco L; Bur D; Brooks H; Török M; Landmann L; Stieger B; Krähenbühl S
    Cell Mol Life Sci; 2008 May; 65(10):1596-608. PubMed ID: 18408886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of OCTN2-mediated transport of carnitine by etoposide.
    Hu C; Lancaster CS; Zuo Z; Hu S; Chen Z; Rubnitz JE; Baker SD; Sparreboom A
    Mol Cancer Ther; 2012 Apr; 11(4):921-9. PubMed ID: 22389472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition.
    Inano A; Sai Y; Kato Y; Tamai I; Ishiguro M; Tsuji A
    Drug Metab Pharmacokinet; 2004 Jun; 19(3):180-9. PubMed ID: 15499185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2.
    Wagner CA; Lükewille U; Kaltenbach S; Moschen I; Bröer A; Risler T; Bröer S; Lang F
    Am J Physiol Renal Physiol; 2000 Sep; 279(3):F584-91. PubMed ID: 10966938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Na(+)-coupled transport of L-carnitine via high-affinity carnitine transporter OCTN2 and its subcellular localization in kidney.
    Tamai I; China K; Sai Y; Kobayashi D; Nezu J; Kawahara E; Tsuji A
    Biochim Biophys Acta; 2001 Jun; 1512(2):273-84. PubMed ID: 11406104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional analysis of pharmacogenetic variants of human organic cation/carnitine transporter 2 (hOCTN2) identified in Singaporean populations.
    Toh DS; Murray M; Pern Tan K; Mulay V; Grewal T; Lee EJ; Zhou F
    Biochem Pharmacol; 2011 Dec; 82(11):1692-9. PubMed ID: 21864509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model.
    Okura T; Kato S; Deguchi Y
    Drug Metab Pharmacokinet; 2014; 29(1):69-74. PubMed ID: 23877104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caveolin-1--a novel interacting partner of organic cation/carnitine transporter (Octn2): effect of protein kinase C on this interaction in rat astrocytes.
    Czeredys M; Samluk Ł; Michalec K; Tułodziecka K; Skowronek K; Nałęcz KA
    PLoS One; 2013; 8(12):e82105. PubMed ID: 24349196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of OCTN2 and OCTN3 in the apical membrane of rat renal cortex and medulla.
    Cano MM; Calonge ML; Ilundain AA
    J Cell Physiol; 2010 May; 223(2):451-9. PubMed ID: 20112288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
    Ohashi R; Tamai I; Yabuuchi H; Nezu JI; Oku A; Sai Y; Shimane M; Tsuji A
    J Pharmacol Exp Ther; 1999 Nov; 291(2):778-84. PubMed ID: 10525100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis.
    Ekins S; Diao L; Polli JE
    Mol Pharm; 2012 Apr; 9(4):905-13. PubMed ID: 22339151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5).
    Kou L; Sun R; Ganapathy V; Yao Q; Chen R
    Expert Opin Ther Targets; 2018 Aug; 22(8):715-726. PubMed ID: 30016594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular cloning and functional characterization of the OCTN2 transporter at the RBE4 cells, an in vitro model of the blood-brain barrier.
    Friedrich A; Prasad PD; Freyer D; Ganapathy V; Brust P
    Brain Res; 2003 Apr; 968(1):69-79. PubMed ID: 12644265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment.
    Ohnishi S; Okamura N; Sakamoto S; Hasegawa H; Norikura R; Kanaoka E; Takahashi K; Horie K; Sakamoto K; Baba T
    Drug Metab Pharmacokinet; 2008; 23(4):293-303. PubMed ID: 18762717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between pivaloylcarnitine and L-carnitine transport into L6 cells overexpressing hOCTN2.
    Todesco L; Bodmer M; Vonwil K; Häussinger D; Krähenbühl S
    Chem Biol Interact; 2009 Aug; 180(3):472-7. PubMed ID: 19539806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human macrophage differentiation induces OCTN2-mediated L-carnitine transport through stimulation of mTOR-STAT3 axis.
    Ingoglia F; Visigalli R; Rotoli BM; Barilli A; Riccardi B; Puccini P; Milioli M; Di Lascia M; Bernuzzi G; Dall'Asta V
    J Leukoc Biol; 2017 Mar; 101(3):665-674. PubMed ID: 27733576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5).
    Tahara H; Yee SW; Urban TJ; Hesselson S; Castro RA; Kawamoto M; Stryke D; Johns SJ; Ferrin TE; Kwok PY; Giacomini KM
    J Pharmacol Exp Ther; 2009 Apr; 329(1):262-71. PubMed ID: 19141711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycosylation of the OCTN2 carnitine transporter: study of natural mutations identified in patients with primary carnitine deficiency.
    Filippo CA; Ardon O; Longo N
    Biochim Biophys Acta; 2011 Mar; 1812(3):312-20. PubMed ID: 21126579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart.
    Iwata D; Kato Y; Wakayama T; Sai Y; Kubo Y; Iseki S; Tsuji A
    Drug Metab Pharmacokinet; 2008; 23(3):207-15. PubMed ID: 18574325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The activity and surface presence of organic cation/carnitine transporter OCTN2 (SLC22A5) in breast cancer cells depends on AKT kinase.
    Papierniak-Wyglądała A; Lamch W; Jurewicz E; Nałęcz KA
    Arch Biochem Biophys; 2023 Jul; 742():109616. PubMed ID: 37187422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.